{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-365556","form_type":"8-K","ticker":"GENB","cik":"0002100782","company_name":"Generate Biomedicines, Inc.","filed_at":"2026-08-25T23:28:57+00:00","discovered_at":"2026-08-26T10:05:00.447955+00:00","generated_at":"2026-08-26T10:05:50.338513+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Generate:Biomedicines reveals GB-0895 data: ~98-day half-life, 6-month biomarker control","bullets":["Phase 1 (GB-0895-101): single 300 mg SC cuts BEC, FeNO, IL-5, IL-13 in mild-moderate asthma for ≥6 months; ~98-day half-life.","COPD Part C (N=40): biomarker reductions from Month 1 sustained ≥6 months; 300 mg comparable to 600 mg; no related SAEs.","Phase 3 trials SOLAIRIA-1 (NCT07276724) & SOLAIRIA-2 (NCT07359846) each N=786, severe uncontrolled asthma; primary endpoint AAER at 52 weeks.","GB-0895 well-tolerated: majority of TEAEs mild-moderate; all ISRs Grade 1; no anti-drug antibody impact on half-life."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-365556","json":"https://secwatch.observer/filing/0001193125-26-365556.json","markdown":"https://secwatch.observer/filing/0001193125-26-365556.md","text":"https://secwatch.observer/filing/0001193125-26-365556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2100782/000119312526365556/0001193125-26-365556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2100782/000119312526365556/ck0002100782-20260825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-26T10:05:50.338513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}